INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) diagnostics would greatly benefit from more accurate, non-invasive techniques for the detection of clinically significant disease, leading to a reduction of over-diagnosis and over-treatment. Multiparametric MRI (mpMRI) is being used increasingly and has proven to be a valuable addition to the PCa diagnostic pathway. A novel biomarker-based risk score (SelectMDx) assessing urinary HOXC6 and DLX1 mRNA expression levels combined with traditional clinical risk factors, was recently developed to predict high-grade PCa (Gleason score >/¼7) upon prostate biopsy and to reduce the number of unnecessary biopsies. The aim of this study was to investigate the correlation between the risk score and mpMRI outcomes.
METHODS: The patients in this retrospective observational cohort were previously included in the validation study of the SelectMDx risk score, in which urine was collected after digital rectal examination (DRE) from men undergoing prostate biopsies based on an elevated serum PSA level (>/¼3.0 ng/ml) and/or suspicious DRE. A subset of patients underwent an mpMRI after prostate biopsies were performed (n¼174). The indications for performing MRI were based on persistent clinical suspicion of PCa after negative prostate biopsies or staging after PCa was found upon biopsy.
RESULTS: 102 of 174 patients (59%) had PCa detected upon prostate biopsy, of which 54 (53%) had high-grade disease and a significantly higher SelectMDx risk score (p<0.001). The median SelectMDx risk score was also significantly higher in patients who had a suspicious lesion on MRI (p<0.001). For 81 mpMRI's the PIRADS classification was reported and there was a positive correlation observed between the risk score and the PIRADS classification ( Figure  1) . A Kruskal-Wallis test indicated a statistically significant difference in SelectMDx risk scores between the different PIRADS groups (p<0.001).
CONCLUSIONS: The novel urinary biomarker-based risk score is a promising tool in PCa detection. This study showed promising results regarding the correlation between the SelectMDx risk score with MRI outcomes. This risk score could potentially guide clinicians in selecting patients at risk for significant PCa for mpMRI. RESULTS: 61.1% (63/103) of clinical Gleason 8 diagnoses were downgraded on surgical pathology after RP, with 60 specimens being downgraded to Gleason 7 (Gleason 4+3 n¼39; Gleason 3+4 n¼21). There were significant in-group differences among the one-year cohorts (p<0.02), with increased pathology downgrading over time that includes an 84.2% (32/38) downgrade rate from 2012-2015. Pathology downgrading is significantly associated with lower PSA at biopsy (median 6.9 vs 9.4 ng/ml, p<0.01), decreased tumor percentage (median 12 vs 15%, p<0.03), and lower percentage of positive margins (47.6 vs 66.7%, p<0.04). It is borderline associated with lower percentage of seminal vesicle invasion (11.1 vs 25.6%, p<0.06) and extracapsular extension (49.2 vs 69.2%, p<0.08). Neoadjuvant treatment (14/103), race, age, and clinical staging were not significantly associated with pathology downgrading.
CONCLUSIONS: The large, increasing percentage of pathology downgrading implies a high rate of over-diagnosis of Gleason 8 scores on biopsy, potentially leading to suboptimal treatment strategies and much patient distress. Our study adds great urgency to the efforts refining PC diagnostic techniques.
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MP33-19 AN EXOME-WIDE ASSOCIATION STUDY REPLICATED FOR PROSTATE CANCER IN KOREAN POPULATION
INTRODUCTION AND OBJECTIVES: To date, more than 300 susceptibility loci associated with prostate cancer (PCa) have been identified mainly from studies of European ancestry populations with much less contributions from Asian populations. As there was a genetic difference according to ethnic groups, we performed the first Korean population based exome wide association study for PCa in this study.
METHODS: Our study was performed in a two-stage design. Stage I e 1,001 PCa patients using a custom HumanExome e424 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
